RVL Pharmaceuticals Q2 Adj. EPS $(0.10) Beats $(0.13) Estimate, Sales $8.26M Miss $10.38M Estimate
Portfolio Pulse from Benzinga Newsdesk
RVL Pharmaceuticals (NASDAQ:RVLP) reported Q2 losses of $(0.24) per share, missing the analyst consensus estimate of $(0.13) by 84.62%. This is a 71.43% decrease over losses from the same period last year. The company also reported quarterly sales of $8.26 million, missing the analyst consensus estimate of $10.38 million by 20.44%. This is a 2.25% decrease over sales from the same period last year.
August 14, 2023 | 10:55 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RVL Pharmaceuticals reported a larger than expected loss and lower than expected sales for Q2. This could negatively impact the company's stock price in the short term.
RVL Pharmaceuticals reported a larger than expected loss and lower than expected sales for Q2. This negative earnings surprise is likely to lead to a decrease in the company's stock price in the short term as it indicates that the company's financial performance is worse than what the market was expecting.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100